Qiong Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qiong Lin has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Dalu Cheng
Department of Clinical Medicine Fujian Medical University Fuzhou Fujian China
1 shared publicationGang Chen
Department of orthopedics Fujian Medical University Union Hospital Fuzhou Fujian China
1 shared publication- Jiandong Li
Department of orthopedics Fujian Medical University Union Hospital Fuzhou Fujian China
1 shared publication Jingjing Gong
Department of Cardiology The First Affiliated Hospital of Fujian Medical University Fuzhou Fujian China
1 shared publication- Penghong Chen
Department of Plastic Surgery The Second Affiliated Hospital of Fujian Medical University Fuzhou Fujian China
1 shared publication Zhitao Shangguan
Department of orthopedics Fujian Medical University Union Hospital Fuzhou Fujian China
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by Wiley in Aging Cell
- Vol. 25 (10) , e70739
Prodh2‐Mediated Mitochondrial Stress Drives TNF ‐α‐Induced Myoblast Dysfunction and Sarcopenia in COPD
Sarcopenia in chronic obstructive pulmonary disease (COPD) is driven by elevated tumor necrosis factor‐alpha (TNF‐α), yet the underlying mechanism remains unclear. Here, we identify the mitochondrial metabolic enzyme Prodh2 as a pivotal mediator. Prodh2 was significantly upregulated in sarcopenic COPD patients and a corresponding mouse model. Mechanistically, TNF‐α induced Prodh2 transcription in myoblasts via a p53‐dependent pathway. This upregulation triggered excessive mitochondrial reactive oxygen species, leading to the release of mitochondrial DNA (mtDNA). Cytosolic mtDNA subsequently activated the cGAS/STING innate immune pathway, causing myoblast apoptosis, proliferation arrest, and atrophy. While Prodh2 knockdown reversed these effects in vitro, muscle‐specific knockdown of Prodh2 in vivo critically ameliorated muscle atrophy and restored strength. Our study unveils a novel TNF‐α‐p53‐Prodh2‐cGAS/STING axis that links chronic inflammation to sarcopenia through metabolic‐immune crosstalk, validating Prodh2 as a promising therapeutic target.
- 1 October 2026
- Published by Wiley in Aging Cell
- Vol. 25 (10) , e70739
Open AccessProdh2‐Mediated Mitochondrial Stress Drives TNF ‐α‐Induced Myoblast Dysfunction and Sarcopenia in COPD
Sarcopenia in chronic obstructive pulmonary disease (COPD) is driven by elevated tumor necrosis factor‐alpha (TNF‐α), yet the underlying mechanism remains unclear. Here, we identify the mitochondrial metabolic enzyme Prodh2 as a pivotal mediator. Prodh2 was significantly upregulated in sarcopenic COPD patients and a corresponding mouse model. Mechanistically, TNF‐α induced Prodh2 transcription in myoblasts via a p53‐dependent pathway. This upregulation triggered excessive mitochondrial reactive oxygen species, leading to the release of mitochondrial DNA (mtDNA). Cytosolic mtDNA subsequently activated the cGAS/STING innate immune pathway, causing myoblast apoptosis, proliferation arrest, and atrophy. While Prodh2 knockdown reversed these effects in vitro, muscle‐specific knockdown of Prodh2 in vivo critically ameliorated muscle atrophy and restored strength. Our study unveils a novel TNF‐α‐p53‐Prodh2‐cGAS/STING axis that links chronic inflammation to sarcopenia through metabolic‐immune crosstalk, validating Prodh2 as a promising therapeutic target.